Join Professor John Camm and Dr Stuart Connolly in their discussion of the full study publication of the ANNEXA-4 study: Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.
Register your email and provide your feedback
To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey
The ANNEXA-4 trial is a multicentre, prospective, open-label, single-group study of andexanet alfa in patients with acute major bleeding. The study involved over 350 patients and evaluated both the efficacy and safety of andexanet alfa. This 30-minute journal club will explore the insights and impact of the full analysis of the published study ‘Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors’.
View abstract Access full paper